Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

High-throughput discovery of constitutive promoters to drive strong expression of next-generation gene circuits in CAR-NK and -T cells

Tuesday, October 31, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the high-throughput discovery of constitutive promoters aimed at enhancing gene circuit technology for CAR-NK and -T cells. This advancement is expected to drive strong expression of next-generation gene circuits, potentially improving treatment options for conditions like Acute Myeloid Leukemia. The research highlights the innovative approach taken by the team.
Price reaction · baseline $2.798 (2023-10-31 close) · hit after-hours · 3 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
+3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • High-throughput discovery enhances gene circuit technology.
  • Strong expression of gene circuits in CAR-NK and -T cells.
  • Potential advancements in treatment for Acute Myeloid Leukemia.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

• About Overview Team Board of Directors Scientific Advisory Board
• Approach Overview Gene Circuit Technology Platform
• Research & Pipeline Pipeline SENTI-202 for Acute Myeloid Leukemia Presentations & Publications Expanded Access to Investigational Medicines
• Investors Overview Press Releases Events and Presentations Analyst Coverage Financials and Filings Corporate Governance Documents and Charters Leadership Team Board of Directors Committee Composition Stock Information Investor Resources FAQ Email Alerts Contact Us
• Careers
• Overview
• Team
• Board of Directors
• Scientific Advisory Board
• Overview
• Gene Circuit Technology Platform
• Pipeline
• SENTI-202 for Acute Myeloid Leukemia
• Presentations & Publications
• Expanded Access to Investigational Medicines
• Overview
• Press Releases
• Events and Presentations
• Analyst Coverage
• Financials and Filings
• Corporate Governance Documents and Charters Leadership Team Board of Directors Committee Composition
• Stock Information
• Investor Resources FAQ Email Alerts Contact Us
• Documents and Charters
• Leadership Team
• Board of Directors
• Committee Composition
• FAQ
• Email Alerts
• Contact Us
SITC Annual Meeting Tony Hua, Nicholas W. Frankel, Ippolito I. Caradonna, Assen Roguev, Karen L. Chu, Russell M. Gordley, Kanya Rajangam and Timothy K. Lu

View PDF

Frequently Asked Questions

What is the focus of the article?

The article focuses on the discovery of constitutive promoters to enhance gene circuit technology for CAR-NK and -T cells.

How does this discovery impact CAR-NK and -T cells?

This discovery aims to drive strong expression of next-generation gene circuits in CAR-NK and -T cells.

What potential applications are mentioned?

The advancements could improve treatment options for conditions like Acute Myeloid Leukemia.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare gene circuits CAR-NK cells CAR-T cells Acute Myeloid Leukemia
Last updated: Oct 31, 2023

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →